MICHELLE FARLOW: Open Payments
NPI 1790034569 · BERLIN, MD. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$427 in 20 payments from 8 companies in 2025. Trend: 2023 $1,301 · 2024 $330 · 2025 $427
Food & beverage: $427
| Company | Payments | Amount |
|---|---|---|
| Corcept Therapeutics | 5 | $157 |
| Novo Nordisk Inc | 5 | $92 |
| Lilly USA, LLC | 4 | $85 |
| Phathom Pharmaceuticals, Inc. | 2 | $29 |
| Exact Sciences Corporation | 1 | $18 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $17 |
| Evofem Biosciences, Inc. | 1 | $16 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 1 | $13 |
Products named: Korlym, MOUNJARO, Wegovy, VOQUEZNA, Cologuard Collection Kit, EOHILIA, Ozempic, Phexxi.
Industry payments across MD — which companies pay providers there.
